Orphan designation granted for Cushing’s syndrome mAb
The European Commission has granted orphan designation to asedebart (Lu AG13909) to brain health biopharmaceutical company Lundbeck’s novel investigational anti-ACTH monoclonal antibody (mAb), for the treatment of Cushing’s syndrome of endogenous origin. Cushing’s syndrome of endogenous origin includes both ACTH-dependent and ACTH-independent forms. ACTH-dependent Cushing’s syndrome is a rare, serious endocrine… Read More